close

LATEST POSTS from Anne-Lise Berthier

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility   The FDA has granted commercial licensure approval for Novartis' Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma®, as well as produce…..

Microbiota medicine: towards clinical revolution

Microbiota medicine: towards clinical revolution 21 high-level authors and members of the International Society of Microbiota, coming from 8 countries and more than 10 reputable institutions published a new strategic report titled “Microbiota medicine: towards clinical revolution”. Published in the Journal of Translational Medicine, this stunning review confirms that microbiota…..

On World Bipolar Day ALCEDIAG announces EIT Health supported EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorder

On World Bipolar Day ALCEDIAG announces EIT Health supported EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorder   ALCEDIAG announced the launch of the EDIT-B Consortium, supported by the European Institute of Innovation and Technology for Health (EIT Health). This newly formed European public-private partnership aims at advancing…..

Touchlight and Versameb announce GMP manufacturing supply agreement to support the development of novel mRNA-based therapeutics

Touchlight and Versameb announce GMP manufacturing supply agreement to support the development of novel mRNA-based therapeutics Touchlight, a UK biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has concluded a development and manufacturing pipeline agreement with Versameb, a Swiss pre-clinical stage company focused on discovering and…..

MaaT Pharma and SkyePharma to establish the first microbiome-based therapeutics manufacturing facility in France

MaaT Pharma and SkyePharma to establish the first microbiome-based therapeutics manufacturing facility in France MaaT Pharma and Skyepharma have entered a partnership agreement to build SkyeHub Bioproduction, a new manufacturing facility near Lyon. This new plant will be France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based therapeutics. SkyeHub Bioproduction…..